Get the Stockscreener App
0.829
2.47%
-0.021
After Hours:
.82
-0.009
-1.09%
Tempest Therapeutics Inc stock is traded at $0.829, with a volume of 285.20K.
It is down -2.47% in the last 24 hours and down -25.32% over the past month.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
See More
Previous Close:
$0.85
Open:
$0.8677
24h Volume:
285.20K
Relative Volume:
0.12
Market Cap:
$13.71M
Revenue:
-
Net Income/Loss:
$-43.10M
P/E Ratio:
-0.1335
EPS:
-6.2098
Net Cash Flow:
$-26.38M
1W Performance:
-14.36%
1M Performance:
-25.32%
6M Performance:
-52.36%
1Y Performance:
-82.19%
1-Day Range:
$0.815
$0.8946
1-Week Range:
$0.7653
$1.09
52-Week Range:
$0.7432
$6.115
Tempest Therapeutics Inc Stock (TPST) Company Profile
Name
Tempest Therapeutics Inc
Sector
Industry
Phone
415-798-8589
Address
2000 SIERRA POINT PARKWAY, BRISBANE
Compare TPST vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TPST
Tempest Therapeutics Inc
|
0.829 | 13.71M | 0 | -43.10M | -26.38M | -6.2098 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-26 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-10-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-10-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Feb-08-24 | Initiated | Jefferies | Buy |
Tempest Therapeutics Inc Stock (TPST) Latest News
H.C. Wainwright Maintains Tempest Therapeutics(TPST.US) With Buy Rating, Cuts Target Price to $7 - Moomoo
Tempest Therapeutics, Inc. (TPST) Stock Price, News, Quote & History - Yahoo! Finance Canada
symbol__ Stock Quote Price and Forecast - CNN
Tempest Therapeutics Is Maintained at Buy by HC Wainwright & Co. - Moomoo
Tempest Therapeutics appoints Nancy Freda-Smith to board - Investing.com
Ralph Lauren's former audit and risk chief joins Tempest's board - Stock Titan
$Tempest Therapeutics (TPST.US)$[Share Link: Join us in the TradersLink | Join main group chat.] - Moomoo
Tempest Therapeutics (TPST) Slides 14.57% to $0.83, Testing Support Near $0.79Synthetic Short - siam.in
Form 8K Tempest Therapeutics Inc For: 17 September By Investing.com - Investing.com Nigeria
Tempest Therapeutics Expands In Vivo CAR-T Collaboration - TipRanks
Tempest Therapeutics, Inc.Common Stock (NQ: TPST - The Chronicle-Journal
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
$Tempest Therapeutics (TPST.US)$ - Moomoo
TPST Stock Slides As Dilutive Financing Overhang Builds - StocksToTrade
$Tempest Therapeutics (TPST.US)$ i like the generosity ill 🦁 it everytime - Moomoo
Tempest Therapeutics (TPST) Stock Climbs Over 66% After Hours: Here's Why - webull.com
Tempest Therapeutics (TPST) Stock Surges Wednesday: What's Driving the Action? - Benzinga
TPST Stock Spikes As New In Vivo CAR-T Deal Ignites Momentum - StocksToTrade
Biotech Pre-Market Movers: MEDS, TPST, CUPR Chart The Course - RTTNews
TPST Stock Spikes As Tempest Therapeutics Bets On In Vivo CAR-T - StocksToTrade
TPST Stock Jumps As Tempest Strikes In Vivo CAR-T Deal - timothysykes.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
TPST Stock Jumps As Tempest Therapeutics Expands In Vivo CAR-T Pipeline - StocksToTrade
Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket - Benzinga
Tempest Therapeutics Shares Surge 66.53% After Hours on CAR-T DealTempest Therapeutics (NASDAQ:TPST) - Benzinga
After-Hours Movers Sept. 15, 2026: WAFU, TPST, NAMI Gain; SOBR, FEED Fall - ChartMill
Tempest Therapeutics Raises $2.5 Million in Private Placement - Minichart
Tempest Therapeutics Gains Option to License New In-Body CAR-T Technology From Senlang - marketscreener.com
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Form 8K Tempest Therapeutics Inc For: 15 September By Investing.com - Investing.com Nigeria
Tempest Therapeutics Announces New Private Warrant Financing - TipRanks
Tempest Therapeutics stock surges on Senlang CAR-T deal By Investing.com - Investing.com Canada
Tempest Therapeutics stock surges on Senlang CAR-T deal - Investing.com
Tempest Therapeutics enters option deal for CAR-T platform - Investing.com
Tempest Therapeutics enters option deal for CAR-T platform By Investing.com - Investing.com India
Tempest Therapeutics Announces Exclusive Option Agreement with Senlang for CD7-Targeted Lentiviral In Vivo CAR-T Platform and BCMA/GPRC5D Candidate - Quiver Quantitative
Tempest Therapeutics raises $2.5M in private placement By Investing.com - Investing.com Australia
Tempest Therapeutics, Inc. announced that it expects to receive $2.500001 million in funding - marketscreener.com
Tempest Therapeutics Announces Up to $7.5 Million Private Placement - markets.businessinsider.com
Tempest Therapeutics raises $2.5M in private placement - Investing.com
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Tempest Therapeutics secures $50M equity purchase agreement with Lincoln Park - scanx.trade
Tempest Therapeutics CEO to present at H.C. Wainwright Global Investment Conference - Bitget
A biotech CEO will speak Sept. 15; Tempest will archive the webcast - Stock Titan
Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewswire
Tempest Therapeutics, Inc. SEC Filing (Sep 1, 2026) - Stock Titan
Tempest Therapeutics (TPST) Slips 1.85% to $1.06 as Shares Test Support at $1.01Cup and Handle - siam.in
Tempest TherapeuticsJustin Trojanowski To Resign As Principal Financial Officer And Principal Accounting Officer Effective Sept 1SEC Filing - tradingview.com
Tempest Therapeutics Inc Stock (TPST) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):